 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- QBS72S / Quadriga Biosci
Safety lead-in results for QBS10072S in the Individual Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial, a randomized adaptive platform trial for newly diagnosed MGMT unmethylated glioblastoma (Hall B3) - Nov 7, 2024 - Abstract #SNO2024SNO_1028;
- QBS72S / Quadriga Biosci
Safety lead-in results for QBS10072S in the Individual Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial, a randomized adaptive platform trial for newly diagnosed MGMT unmethylated glioblastoma (Hall A3) - Nov 7, 2024 - Abstract #SNO2024SNO_407;
- || Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Trial completion date, Trial primary completion date: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Oct 17, 2024
P2, N=460, Recruiting, Sponsor: Patrick Wen, MD
Trial completion date: Dec 2025 --> Apr 2027 | Trial primary completion date: Mar 2025 --> Feb 2027
- ||| Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Enrollment change: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Jul 3, 2024
P2, N=460, Recruiting, Sponsor: Patrick Wen, MD
Trial completion date: Dec 2025 --> Apr 2027 | Trial primary completion date: Mar 2025 --> Feb 2027 N=250 --> 460
- QBS72S / Quadriga Biosci
Phase classification: Study Assessing QBS72S for Treating Brain Metastases (clinicaltrials.gov) - Feb 23, 2024
P2, N=40, Recruiting, Sponsor: Melanie Hayden Gephart
N=250 --> 460 Phase classification: P2a --> P2
- | QBS72S / Quadriga Biosci
Journal: Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas. (Pubmed Central) - Jan 9, 2024
The findings demonstrated decreased survival of T-cell lymphoma lines with both compounds. Overall, the results demonstrate that LAT1 is a valuable biomarker for aggressive T-cell lymphoma counterparts and QBS10072S and QBS10096S are successful therapeutic options for these aggressive diseases.
- || Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Trial primary completion date: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Aug 9, 2023
P2, N=250, Recruiting, Sponsor: Patrick Wen, MD
Overall, the results demonstrate that LAT1 is a valuable biomarker for aggressive T-cell lymphoma counterparts and QBS10072S and QBS10096S are successful therapeutic options for these aggressive diseases. Trial primary completion date: Dec 2024 --> Mar 2025
- |||| Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Enrollment open, Trial completion date, Trial primary completion date: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Aug 8, 2023
P2, N=250, Recruiting, Sponsor: Patrick Wen, MD
Trial primary completion date: Dec 2024 --> Mar 2025 Active, not recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | QBS72S / Quadriga Biosci
Trial completion date, Trial primary completion date: Study Assessing QBS72S for Treating Brain Metastases (clinicaltrials.gov) - Jan 31, 2023
P2a, N=40, Recruiting, Sponsor: Melanie Hayden Gephart
Active, not recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Oct 2025 --> Aug 2026 | Trial primary completion date: Apr 2024 --> Feb 2025
- || QBS72S / Quadriga Biosci
Trial completion, Enrollment change, Metastases: Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (clinicaltrials.gov) - Jan 18, 2023
P1, N=15, Completed, Sponsor: Quadriga Biosciences, Inc.
Trial completion date: Oct 2025 --> Aug 2026 | Trial primary completion date: Apr 2024 --> Feb 2025 Active, not recruiting --> Completed | N=50 --> 15
- | QBS72S / Quadriga Biosci
Enrollment open: Study Assessing QBS72S for Treating Brain Metastases (clinicaltrials.gov) - Oct 17, 2022
P2a, N=35, Recruiting, Sponsor: Melanie Hayden Gephart
Active, not recruiting --> Completed | N=50 --> 15 Not yet recruiting --> Recruiting
- || QBS72S / Quadriga Biosci
Enrollment closed, Metastases: Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (clinicaltrials.gov) - Sep 16, 2022
P1, N=50, Active, not recruiting, Sponsor: Quadriga Biosciences, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | QBS72S / Quadriga Biosci
Trial initiation date: Study Assessing QBS72S for Treating Brain Metastases (clinicaltrials.gov) - Jun 30, 2022
P2a, N=35, Not yet recruiting, Sponsor: Melanie Hayden Gephart
Recruiting --> Active, not recruiting Initiation date: Apr 2022 --> Jul 2022
- | QBS72S / Quadriga Biosci
Trial completion date, Trial primary completion date, Metastases: Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (clinicaltrials.gov) - Apr 19, 2022
P1, N=50, Recruiting, Sponsor: Quadriga Biosciences, Inc.
Initiation date: Apr 2022 --> Jul 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- | QBS72S / Quadriga Biosci
New P2a trial: Study Assessing QBS72S for Treating Brain Metastases (clinicaltrials.gov) - Mar 31, 2022
P2a, N=35, Not yet recruiting, Sponsor: Melanie Hayden Gephart
- | QBS10072S / Quadriga Biosci
Journal: A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer. (Pubmed Central) - Mar 26, 2022
Treatment options for TNBC leptomeningeal metastasis are limited and are mostly palliative. Our study demonstrates significant efficacy of the brain-penetrating agent QBS10072S against TNBC brain metastasis and leptomeningeal spread.
- || Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Trial completion date, Trial primary completion date: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Jan 19, 2022
P2, N=250, Active, not recruiting, Sponsor: Patrick Y. Wen, MD
Our study demonstrates significant efficacy of the brain-penetrating agent QBS10072S against TNBC brain metastasis and leptomeningeal spread. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
- | temozolomide / Generic mfg.
Journal: A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma. (Pubmed Central) - Oct 15, 2021
In orthotopic GBM xenografts, QBS10072S treatment significantly delayed tumorigenesis and prolonged animal survival compared to the vehicle without adverse effects. Conclusion QBS10072S is a novel BBB-permeable chemotherapeutic agent with the potential to treat TMZ-resistant and recurrent GBM as monotherapy or in combination with radiation treatment.
- ||| Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Enrollment closed: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Aug 11, 2021
P2, N=250, Active, not recruiting, Sponsor: Patrick Y. Wen, MD
Conclusion QBS10072S is a novel BBB-permeable chemotherapeutic agent with the potential to treat TMZ-resistant and recurrent GBM as monotherapy or in combination with radiation treatment. Recruiting --> Active, not recruiting
- || Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Trial completion date, Trial primary completion date: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Feb 26, 2021
P2, N=250, Recruiting, Sponsor: Patrick Y. Wen, MD
Recruiting --> Active, not recruiting Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Feb 2021 --> Dec 2021
- || QBS72S / Quadriga Biosci
Enrollment open, Metastases: Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (clinicaltrials.gov) - Jul 6, 2020
P1, N=50, Recruiting, Sponsor: Quadriga Biosciences, Inc.
Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Feb 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- || QBS72S / Quadriga Biosci
New P1 trial, Metastases: Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (clinicaltrials.gov) - Jun 11, 2020
P1, N=50, Not yet recruiting, Sponsor: Quadriga Biosciences, Inc.
- || Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Trial completion date, Trial primary completion date: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Feb 26, 2020
P2, N=280, Recruiting, Sponsor: Patrick Y. Wen, MD
Not yet recruiting --> Recruiting Trial completion date: May 2021 --> May 2022 | Trial primary completion date: Feb 2020 --> Feb 2021
- | Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Trial primary completion date: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Aug 28, 2019
P2, N=280, Recruiting, Sponsor: Patrick Y. Wen, MD
Trial completion date: May 2021 --> May 2022 | Trial primary completion date: Feb 2020 --> Feb 2021 Trial primary completion date: May 2019 --> Feb 2020
- |||| Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
Enrollment open: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Jan 10, 2017
P2, N=280, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: May 2019 --> Feb 2020 Not yet recruiting --> Recruiting
- ||||| Nerlynx (neratinib) / Puma, QBS72S / Quadriga Biosci
New P2 trial: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov) - Nov 30, 2016
P2, N=280, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute